[
    {
        "pregunta": "1. What are the primary objectives of the 2015 recommendations for the management of Polymyalgia Rheumatica (PMR)?",
        "respuesta": "The primary objectives of the 2015 recommendations for the management of Polymyalgia Rheumatica (PMR) include:\n\n- Adoption of a safe and specific approach to ascertain the PMR case definition.\n- Directing clinical evaluation towards the exclusion of relevant mimicking conditions.\n- Implementing an agreed, validated core outcome set for future studies in PMR.\n- Maximizing the power of studies, facilitating regulatory approvals, and allowing meta-analysis through robust trial designs.\n- Providing specific recommendations for the management of PMR based on consensus and expert opinion.\n\nIf you require more detailed information, I recommend referring to the documents \"2015 Recommendations for the Management of Polymyalgia Rheumatica\" and \"Principles for the Management of PMR\" for a comprehensive understanding of the objectives and principles outlined.",
        "contexto": [
            "principles for the management of PMR. The group agreed upon several principles deemed to be fundamental aspects of clinical care in PMR as detailed in Box 1. These principles have not directly resulted from the SLR, but are consensus based. They are intended as a framework for the implementation of Box 1. Summary of the 2015 European League Against Rheumatism (EULAR)/American College of Rheumatology (ACR) recommendations for the management of polymyalgia rheumatica (PMR) Target population:",
            "for the management of polymyalgia rheumatica (PMR) Target population: Patients with PMR based on clinician diagnosis which may be supported by currently available diagnostic or classification criteria Overarching principles for the management of PMR: A. Adoption of a safe and specific approach to ascertain the PMR case definition. The clinical evaluation should be directed toward exclusion of relevant mimicking (eg, non-inflammatory, inflammatory (such as giant cell arteritis or rheumatoid",
            "2015 Recommendations for the Management of Polymyalgia Rheumatica A European League Against Rheumatism/American College of Rheumatology Collaborative Initiative  Abbott  Roche  MSD  Bristol-Myers Squibb  GlaxoSmithKline  Celgene  American College of Rheumatology  Mundipharma  Merck  Amgen  Roche/Genentech  Berlin-Chemie  Mesoblast  Novartis  Centocor/Janssen  Sanofi  AbbVie  Genentech  Pfizer  Medac  European League Against Rheumatism  Servier  Ardea   October 2015     October 2015",
            "agents as no prospective trials have been published so far. There is one ongoing randomized study on the The group agreed that future studies in polymyalgia rheumatica (PMR) should be multicenter and properly powered using an agreed, validated core outcome set and a robust trial design that would maximize the power of studies, facilitate regulatory approvals and allow future meta-analysis. Specific research questions: 1. Which outcome measures including patient-related outcomes, and response,",
            "recommendations and are of a general \"overarching\" nature, a concept adapted from earlier EULAR recommendations Specific recommendations. See Box 1 for a summary of the recommendations. A flow-chart for the management of PMR patients is depicted in Figure 1 Recommendation 1: (PICO 1) The panel strongly recommends using GCs instead of NSAIDs in patients with PMR, with the exception of possible short-term use of NSAIDs and/or analgesics in PMR patients with pain related to other conditions (eg,"
        ]
    },
    {
        "pregunta": "2. Who are the target users of these recommendations?",
        "respuesta": "The target users of the 2015 recommendations for the management of Polymyalgia Rheumatica (PMR) are primary, secondary, and tertiary care physicians, including general practitioners (GPs), specialists in general (internal) medicine, and rheumatologists. These recommendations are intended to guide clinical practice in the management of PMR based on expert opinion and clinical evidence.",
        "contexto": [
            "for the management of polymyalgia rheumatica (PMR) Target population: Patients with PMR based on clinician diagnosis which may be supported by currently available diagnostic or classification criteria Overarching principles for the management of PMR: A. Adoption of a safe and specific approach to ascertain the PMR case definition. The clinical evaluation should be directed toward exclusion of relevant mimicking (eg, non-inflammatory, inflammatory (such as giant cell arteritis or rheumatoid",
            "based on clinical evidence and expert opinion including informed patient decision-making. Target population. The target population are patients with PMR based on clinician diagnosis which may be supported by currently available diagnostic or classification criteria Target users. The target users of these recommendations are primary, secondary and tertiary care physicians (that is, general practitioners [GPs], specialists in general [internal] medicine and rheumatologists). Methods For a",
            "principles for the management of PMR. The group agreed upon several principles deemed to be fundamental aspects of clinical care in PMR as detailed in Box 1. These principles have not directly resulted from the SLR, but are consensus based. They are intended as a framework for the implementation of Box 1. Summary of the 2015 European League Against Rheumatism (EULAR)/American College of Rheumatology (ACR) recommendations for the management of polymyalgia rheumatica (PMR) Target population:",
            "2015 Recommendations for the Management of Polymyalgia Rheumatica A European League Against Rheumatism/American College of Rheumatology Collaborative Initiative  Abbott  Roche  MSD  Bristol-Myers Squibb  GlaxoSmithKline  Celgene  American College of Rheumatology  Mundipharma  Merck  Amgen  Roche/Genentech  Berlin-Chemie  Mesoblast  Novartis  Centocor/Janssen  Sanofi  AbbVie  Genentech  Pfizer  Medac  European League Against Rheumatism  Servier  Ardea   October 2015     October 2015",
            "agents as no prospective trials have been published so far. There is one ongoing randomized study on the The group agreed that future studies in polymyalgia rheumatica (PMR) should be multicenter and properly powered using an agreed, validated core outcome set and a robust trial design that would maximize the power of studies, facilitate regulatory approvals and allow future meta-analysis. Specific research questions: 1. Which outcome measures including patient-related outcomes, and response,"
        ]
    },
    {
        "pregunta": "3. What are the overarching principles for the management of PMR as outlined in the guidelines?",
        "respuesta": "The overarching principles for the management of Polymyalgia Rheumatica (PMR) as outlined in the guidelines include:\n\n1. Adoption of a safe and specific approach to ascertain the PMR case definition.\n2. Directing clinical evaluation towards the exclusion of relevant mimicking conditions.\n3. Implementation of an agreed, validated core outcome set for future studies in PMR.\n4. Maximizing the power of studies, facilitating regulatory approvals, and allowing meta-analysis through robust trial designs.\n5. Providing specific recommendations for the management of PMR based on consensus and expert opinion.\n\nThese principles serve as a framework for the implementation of the recommendations and aim to guide clinical care in PMR.",
        "contexto": [
            "principles for the management of PMR. The group agreed upon several principles deemed to be fundamental aspects of clinical care in PMR as detailed in Box 1. These principles have not directly resulted from the SLR, but are consensus based. They are intended as a framework for the implementation of Box 1. Summary of the 2015 European League Against Rheumatism (EULAR)/American College of Rheumatology (ACR) recommendations for the management of polymyalgia rheumatica (PMR) Target population:",
            "these recommendations. None of the panel members disclosed any conflict of interest associated with the development of these recommendations. Discussion See online supplementary file S3 ( http://online We recognize that our recommendations are only partially supported by evidence, and that they do not cover all aspects important for the management of PMR. The group therefore unanimously agreed that the research agenda (containing the evidence gaps related to PMR management) is an important",
            "Results The results of the SLR are reported in a separate manuscript http://onlinelibrary General aspects. These recommendations should be understood as clinical advice and do not dictate the care of a particular patient. The EULAR and ACR consider adherence to these recommendations to be voluntary, with the physician making the ultimate decision to apply them in light of each patient's individual circumstances. Overarching principles for the management of PMR. The group agreed upon several",
            "recommendations and are of a general \"overarching\" nature, a concept adapted from earlier EULAR recommendations Specific recommendations. See Box 1 for a summary of the recommendations. A flow-chart for the management of PMR patients is depicted in Figure 1 Recommendation 1: (PICO 1) The panel strongly recommends using GCs instead of NSAIDs in patients with PMR, with the exception of possible short-term use of NSAIDs and/or analgesics in PMR patients with pain related to other conditions (eg,",
            "for the management of polymyalgia rheumatica (PMR) Target population: Patients with PMR based on clinician diagnosis which may be supported by currently available diagnostic or classification criteria Overarching principles for the management of PMR: A. Adoption of a safe and specific approach to ascertain the PMR case definition. The clinical evaluation should be directed toward exclusion of relevant mimicking (eg, non-inflammatory, inflammatory (such as giant cell arteritis or rheumatoid"
        ]
    },
    {
        "pregunta": "4. What are the recommended assessments that should be conducted prior to prescribing therapy for PMR patients?",
        "respuesta": "The recommended assessments that should be conducted prior to prescribing therapy for Polymyalgia Rheumatica (PMR) patients include:\n\n1. Documentation of a basic laboratory dataset to exclude mimicking conditions and establish a baseline for monitoring therapy. This may include testing for rheumatoid factor and/or anti-cyclic citrullinated peptide.\n\nThese assessments are essential to ensure an accurate diagnosis and appropriate management of PMR. If you have any more questions or need further information, please let me know.",
        "contexto": [
            "for the management of polymyalgia rheumatica (PMR) Target population: Patients with PMR based on clinician diagnosis which may be supported by currently available diagnostic or classification criteria Overarching principles for the management of PMR: A. Adoption of a safe and specific approach to ascertain the PMR case definition. The clinical evaluation should be directed toward exclusion of relevant mimicking (eg, non-inflammatory, inflammatory (such as giant cell arteritis or rheumatoid",
            "agents as no prospective trials have been published so far. There is one ongoing randomized study on the The group agreed that future studies in polymyalgia rheumatica (PMR) should be multicenter and properly powered using an agreed, validated core outcome set and a robust trial design that would maximize the power of studies, facilitate regulatory approvals and allow future meta-analysis. Specific research questions: 1. Which outcome measures including patient-related outcomes, and response,",
            "non-inflammatory, inflammatory (such as giant cell arteritis or rheumatoid arthritis), drug-induced, endocrine, infective and neoplastic) conditions. B. Every case of PMR should have the following assessments prior to the prescription of therapy (primary or secondary care): \" Documentation of a basic laboratory dataset. This will help to exclude mimicking conditions and establish a baseline for monitoring of therapy. This should include rheumatoid factor and/or anti-cyclic citrullinated peptide",
            "principles for the management of PMR. The group agreed upon several principles deemed to be fundamental aspects of clinical care in PMR as detailed in Box 1. These principles have not directly resulted from the SLR, but are consensus based. They are intended as a framework for the implementation of Box 1. Summary of the 2015 European League Against Rheumatism (EULAR)/American College of Rheumatology (ACR) recommendations for the management of polymyalgia rheumatica (PMR) Target population:",
            "Which outcome measures including patient-related outcomes, and response, remission and relapse criteria should be used in PMR? What is the value of a composite score? What are the most relevant treatment targets in PMR? 2. What is the efficacy and safety of different routes of glucocorticoid (GC) administration (oral, intramuscular, intra-articular), different initial GC doses, various GC tapering regimens, and different GC flare doses? 3. What is the efficacy and safety of DMARDs (non-TNFa"
        ]
    },
    {
        "pregunta": "5. Why does the panel strongly recommend using glucocorticoids (GCs) instead of NSAIDs in patients with PMR?",
        "respuesta": "The use of glucocorticoids (GCs) is strongly recommended over NSAIDs in patients with Polymyalgia Rheumatica (PMR) because the relative harm of long-term NSAID use outweighs the possible small benefits in PMR. The panel strongly recommends using GCs instead of NSAIDs in the treatment of PMR based on available evidence and expert opinion. Additionally, NSAIDs may not be as effective in managing the symptoms of PMR compared to GCs.",
        "contexto": [
            "analgesics in PMR patients with pain related to other conditions (eg, co-existing osteoarthritis). No specific recommendation can be made for analgesics. Explanation: The group recommends strongly against the use of NSAIDs compared to GCs in the treatment of PMR since the relative harm of long-term NSAID use (as mainly indicated by external evidence) outweighs the possible small benefits in PMR. No specific recommendation can be made for analgesics. On a basis of consensus, the panel recognized",
            "with respect to glucocorticoid (GC) dosages, tapering strategies, use of disease modifying anti-rheumatic drugs (DMARDs) and duration of treatment. Up to 29-45% of patients with PMR do not adequately respond to GCs within 3-4 weeks. Relapses and long-term GC dependency are common Primary objective of the recommendations. These recommendations are intended for the management of patients with PMR in various settings and are based on clinical evidence and expert opinion including informed patient",
            "can be made for analgesics. On a basis of consensus, the panel recognized that the short-term use of NSAIDs and/or analgesics may be necessary in the setting of pain related to conditions other than PMR. Recommendation 2: (PICO 2) The panel strongly recommends using the minimum effective individualized duration of GC therapy in PMR patients. A more specific recommendation is not possible due to the lack of published evidence on this issue. On a basis of consensus and in accordance with the",
            "recommendations and are of a general \"overarching\" nature, a concept adapted from earlier EULAR recommendations Specific recommendations. See Box 1 for a summary of the recommendations. A flow-chart for the management of PMR patients is depicted in Figure 1 Recommendation 1: (PICO 1) The panel strongly recommends using GCs instead of NSAIDs in patients with PMR, with the exception of possible short-term use of NSAIDs and/or analgesics in PMR patients with pain related to other conditions (eg,",
            "patients with long-standing disease and long-term low-dose GC therapy be managed? 8. What is the cost utility and effectiveness of DMARD use in PMR (versus GC use alone)? 9. What is the value of non-pharmacological therapies in PMR? Particularly, it is assumed but not yet demonstrated that physiotherapy may support preservation of function and reduce the risk of adverse events related to GC use. Patients may benefit from exercise by maintaining muscle mass and function as well as by fall"
        ]
    },
    {
        "pregunta": "6. What is the recommended minimum effective individualized duration of GC therapy for PMR patients?",
        "respuesta": "The recommended minimum effective individualized duration of glucocorticoid (GC) therapy for patients with Polymyalgia Rheumatica (PMR) is not specifically outlined in the provided information. The duration of GC therapy for PMR patients should be individualized based on factors such as the patient's clinical condition, preferences, values, risk factors for GC-related adverse events, comorbidities, concomitant medications, relapse history, and the balance between benefit and harm. Therefore, a specific recommendation on the duration of GC therapy for PMR patients is not available.",
        "contexto": [
            "with respect to glucocorticoid (GC) dosages, tapering strategies, use of disease modifying anti-rheumatic drugs (DMARDs) and duration of treatment. Up to 29-45% of patients with PMR do not adequately respond to GCs within 3-4 weeks. Relapses and long-term GC dependency are common Primary objective of the recommendations. These recommendations are intended for the management of patients with PMR in various settings and are based on clinical evidence and expert opinion including informed patient",
            "assumes a minimum of 12 months of treatment. A more specific statement is not possible because of the lack of PMR studies on this particular topic and because of the multiple subgroups and factors that need to be taken into account. Recommendation 3: (PICOs 3-5) The panel conditionally recommends using the minimum effective GC dose within a range of 12.5-25 mg prednisone equivalent daily as the initial treatment of PMR. A higher initial prednisone dose within this range may be considered in",
            "can be made for analgesics. On a basis of consensus, the panel recognized that the short-term use of NSAIDs and/or analgesics may be necessary in the setting of pain related to conditions other than PMR. Recommendation 2: (PICO 2) The panel strongly recommends using the minimum effective individualized duration of GC therapy in PMR patients. A more specific recommendation is not possible due to the lack of published evidence on this issue. On a basis of consensus and in accordance with the",
            "continuing remission maintenance therapy for a longer duration Ungraded position statement: The duration of glucocorticoid therapy for GPA/MPA should be guided by the patient's clinical condition, preferences, and values. The optimal duration of glucocorticoid therapy for GPA/MPA is not well established. The immunosuppressive effects of glucocorticoids contributing to disease control should be balanced with the toxicities associated with its use. Overall, patients expressed a desire to minimize",
            "evidence on this issue. On a basis of consensus and in accordance with the overarching principles, the group unanimously agreed to choose the minimum effective individualized duration and dose of GCs to balance benefit versus harm after assessing risk factors for GC-related adverse events, comorbidities, concomitant medications, relapses and prolonged therapy. Our recommended GC tapering schedule (see Recommendation 4) assumes a minimum of 12 months of treatment. A more specific statement is"
        ]
    },
    {
        "pregunta": "7. What is the suggested initial prednisone dose range for the treatment of PMR patients?",
        "respuesta": "The suggested initial prednisone dose range for the treatment of Polymyalgia Rheumatica (PMR) patients is between 12.5-25 mg prednisone equivalent daily. A higher initial prednisone dose within this range may be considered in patients with a high risk of relapse and low risk of adverse events, while a lower dose may be preferred in patients with relevant comorbidities and other risk factors for glucocorticoid-related side effects. The use of initial doses below 7.5 mg/day is discouraged, and initial doses above 30 mg/day are strongly recommended against.",
        "contexto": [
            "assumes a minimum of 12 months of treatment. A more specific statement is not possible because of the lack of PMR studies on this particular topic and because of the multiple subgroups and factors that need to be taken into account. Recommendation 3: (PICOs 3-5) The panel conditionally recommends using the minimum effective GC dose within a range of 12.5-25 mg prednisone equivalent daily as the initial treatment of PMR. A higher initial prednisone dose within this range may be considered in",
            "A higher initial prednisone dose within this range may be considered in patients with a high risk of relapse and low risk of adverse events, whereas in patients with relevant comorbidities (eg, diabetes, osteoporosis, glaucoma, etc.) and other risk factors for GC-related side effects, a lower dose may be preferred. The panel discourages conditionally the use of initial doses #7.5 mg/day and strongly recommends against the use of initial doses .30 mg/day. According to the SLR on prognostic",
            "with respect to glucocorticoid (GC) dosages, tapering strategies, use of disease modifying anti-rheumatic drugs (DMARDs) and duration of treatment. Up to 29-45% of patients with PMR do not adequately respond to GCs within 3-4 weeks. Relapses and long-term GC dependency are common Primary objective of the recommendations. These recommendations are intended for the management of patients with PMR in various settings and are based on clinical evidence and expert opinion including informed patient",
            "initial and relapse therapies): Taper daily oral prednisone by 1 mg every 4 weeks (or by 1.25 mg decrements using schedules such as 10/7.5 mg on alternate days, etc.) until discontinuation as long as remission is maintained. In accordance with the overarching principles, the panel agreed upon a strong recommendation to 2574 DEJACO ET AL individualize dose tapering and to regularly monitor PMR patients. Further, the panel proposed general principles for initial and post-relapse tapering of GCs",
            "below the low-dose range (prednisone or equivalent ,5 mg daily). There are no studies available addressing this issue specifically in PMR. Based on clinical experience and because of the concern that adverse events (including disturbance of the hypothalamic-pituitary-adrenal axis) may be higher with divided doses, the group agreed against the general use of divided GC doses in PMR In special situations such as in case of night pain while tapering below the low-dose range (prednisone or"
        ]
    },
    {
        "pregunta": "8. How should the dose-tapering schedules for GC therapy be individualized for PMR patients?",
        "respuesta": "The dose-tapering schedules for glucocorticoid (GC) therapy should be individualized for patients with Polymyalgia Rheumatica (PMR) based on factors such as the patient's clinical condition, preferences, values, risk factors for GC-related adverse events, comorbidities, concomitant medications, relapse history, and the balance between benefit and harm. The general principle is to taper daily oral prednisone by 1 mg every 4 weeks or by similar decrements, such as using schedules like 10/7.5 mg on alternate days until discontinuation as long as remission is maintained. However, the specific tapering schedule should be personalized for each patient's unique circumstances.",
        "contexto": [
            "with respect to glucocorticoid (GC) dosages, tapering strategies, use of disease modifying anti-rheumatic drugs (DMARDs) and duration of treatment. Up to 29-45% of patients with PMR do not adequately respond to GCs within 3-4 weeks. Relapses and long-term GC dependency are common Primary objective of the recommendations. These recommendations are intended for the management of patients with PMR in various settings and are based on clinical evidence and expert opinion including informed patient",
            "initial and relapse therapies): Taper daily oral prednisone by 1 mg every 4 weeks (or by 1.25 mg decrements using schedules such as 10/7.5 mg on alternate days, etc.) until discontinuation as long as remission is maintained. In accordance with the overarching principles, the panel agreed upon a strong recommendation to 2574 DEJACO ET AL individualize dose tapering and to regularly monitor PMR patients. Further, the panel proposed general principles for initial and post-relapse tapering of GCs",
            "Which outcome measures including patient-related outcomes, and response, remission and relapse criteria should be used in PMR? What is the value of a composite score? What are the most relevant treatment targets in PMR? 2. What is the efficacy and safety of different routes of glucocorticoid (GC) administration (oral, intramuscular, intra-articular), different initial GC doses, various GC tapering regimens, and different GC flare doses? 3. What is the efficacy and safety of DMARDs (non-TNFa",
            "proposed general principles for initial and post-relapse tapering of GCs (based on consensus and current clinical practice) but did not fix a schedule as in other guidelines The group suggested prednisone should be tapered by 1 mg/4 weeks or similar once remission is achieved. Again, the panel emphasized the important overall principle of gradual GC reduction without the need to prescribe a fixed schedule. The group further recognized that 1 mg prednisone tablets are not available in all",
            "recommendations are made for patients who are in low disease activity or remission in the face of a paucity of data about when and how best to taper. The panel recommended that careful tapering might be considered if the patient wishes to cut back on their use of DMARDs. However, patients should be closely evaluated during any taper, and if a flare occurs, the prior regimen should be reinstituted promptly. Last, this update includes several recommendations against the use of glucocorticoid"
        ]
    },
    {
        "pregunta": "9. What are the principles for tapering GC doses once remission is achieved in PMR patients?",
        "respuesta": "The principles for tapering glucocorticoid (GC) doses once remission is achieved in patients with Polymyalgia Rheumatica (PMR) include gradually reducing the daily oral prednisone dose by 1 mg every 4 weeks, or using similar decrements such as 10/7.5 mg on alternate days, until discontinuation as long as remission is maintained. This gradual tapering approach should be individualized for each patient based on factors such as their clinical condition, preferences, values, risk factors for GC-related adverse events, and comorbidities. Regular monitoring of PMR patients during the tapering process is recommended to ensure optimal management.\n\nIf you have any more questions or need additional information, please let me know.",
        "contexto": [
            "with respect to glucocorticoid (GC) dosages, tapering strategies, use of disease modifying anti-rheumatic drugs (DMARDs) and duration of treatment. Up to 29-45% of patients with PMR do not adequately respond to GCs within 3-4 weeks. Relapses and long-term GC dependency are common Primary objective of the recommendations. These recommendations are intended for the management of patients with PMR in various settings and are based on clinical evidence and expert opinion including informed patient",
            "initial and relapse therapies): Taper daily oral prednisone by 1 mg every 4 weeks (or by 1.25 mg decrements using schedules such as 10/7.5 mg on alternate days, etc.) until discontinuation as long as remission is maintained. In accordance with the overarching principles, the panel agreed upon a strong recommendation to 2574 DEJACO ET AL individualize dose tapering and to regularly monitor PMR patients. Further, the panel proposed general principles for initial and post-relapse tapering of GCs",
            "proposed general principles for initial and post-relapse tapering of GCs (based on consensus and current clinical practice) but did not fix a schedule as in other guidelines The group suggested prednisone should be tapered by 1 mg/4 weeks or similar once remission is achieved. Again, the panel emphasized the important overall principle of gradual GC reduction without the need to prescribe a fixed schedule. The group further recognized that 1 mg prednisone tablets are not available in all",
            "Which outcome measures including patient-related outcomes, and response, remission and relapse criteria should be used in PMR? What is the value of a composite score? What are the most relevant treatment targets in PMR? 2. What is the efficacy and safety of different routes of glucocorticoid (GC) administration (oral, intramuscular, intra-articular), different initial GC doses, various GC tapering regimens, and different GC flare doses? 3. What is the efficacy and safety of DMARDs (non-TNFa",
            "recommendations are made for patients who are in low disease activity or remission in the face of a paucity of data about when and how best to taper. The panel recommended that careful tapering might be considered if the patient wishes to cut back on their use of DMARDs. However, patients should be closely evaluated during any taper, and if a flare occurs, the prior regimen should be reinstituted promptly. Last, this update includes several recommendations against the use of glucocorticoid"
        ]
    },
    {
        "pregunta": "10. How should physicians approach the application of the guidelines and recommendations for PMR management in clinical practice?",
        "respuesta": "Physicians should apply the guidelines and recommendations for Polymyalgia Rheumatica (PMR) management in clinical practice by considering them as voluntary clinical advice. The EULAR and ACR emphasize that adherence to these recommendations is at the discretion of the physician, who should make the final decision based on each patient's individual circumstances. The overarching principles for the management of PMR, outlined by consensus, serve as a fundamental framework for implementing the recommendations in clinical care. It is essential for physicians to personalize the treatment approach for each PMR patient, taking into account factors such as clinical condition, preferences, comorbidities, and risk factors for adverse events related to glucocorticoid therapy. Regular monitoring and adapting treatment plans accordingly are key aspects of managing PMR effectively.\n\nIf you have any more questions or need further information, please let me know.",
        "contexto": [
            "Results The results of the SLR are reported in a separate manuscript http://onlinelibrary General aspects. These recommendations should be understood as clinical advice and do not dictate the care of a particular patient. The EULAR and ACR consider adherence to these recommendations to be voluntary, with the physician making the ultimate decision to apply them in light of each patient's individual circumstances. Overarching principles for the management of PMR. The group agreed upon several",
            "principles for the management of PMR. The group agreed upon several principles deemed to be fundamental aspects of clinical care in PMR as detailed in Box 1. These principles have not directly resulted from the SLR, but are consensus based. They are intended as a framework for the implementation of Box 1. Summary of the 2015 European League Against Rheumatism (EULAR)/American College of Rheumatology (ACR) recommendations for the management of polymyalgia rheumatica (PMR) Target population:",
            "recommendations and are of a general \"overarching\" nature, a concept adapted from earlier EULAR recommendations Specific recommendations. See Box 1 for a summary of the recommendations. A flow-chart for the management of PMR patients is depicted in Figure 1 Recommendation 1: (PICO 1) The panel strongly recommends using GCs instead of NSAIDs in patients with PMR, with the exception of possible short-term use of NSAIDs and/or analgesics in PMR patients with pain related to other conditions (eg,",
            "DMARDs yield the best efficacy/safety profile? 5. What is the optimal strategy for shared primary and specialty care including recommendations for specialist referral? How can patients be better involved in treatment decisions, and are there any decision aids? What is the role of self-management? 6. What is the value of tight control (ie, treat to target) versus conventional management strategies in PMR? 7. How should patients with long-standing disease and long-term low-dose GC therapy be",
            "these recommendations. None of the panel members disclosed any conflict of interest associated with the development of these recommendations. Discussion See online supplementary file S3 ( http://online We recognize that our recommendations are only partially supported by evidence, and that they do not cover all aspects important for the management of PMR. The group therefore unanimously agreed that the research agenda (containing the evidence gaps related to PMR management) is an important"
        ]
    }
]